BMCM
AKTX

Bryn Mawr Capital Management’s Akari Therapeutics AKTX Stock Holding History

Bryn Mawr Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125
Closed -$17K – 394
2023
Q2 		$17K Hold
125
– – ﹤0.01% 282
2023
Q1 		$18.2K Hold
125
– – ﹤0.01% 267
2022
Q4 		$47K Hold
125
– – 0.01% 265
2022
Q3 		$63K Hold
125
– – 0.02% 138
2022
Q2 		$100K Hold
125
– – 0.03% 149
2022
Q1 		$120K Hold
125
– – 0.03% 158
2021
Q4 		$150K Buy
+125
New +$161K 0.06% 107

Other funds holding AKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

Bryn Mawr Capital Management's AKTX Position: Q3 2023 in Review

Bryn Mawr Capital Management sold out of Akari Therapeutics (AKTX) in Q3 2023, closing a stake of 125 shares — an estimated $17K sold.

Bryn Mawr Capital Management first reported a position in AKTX in Q4 2021 and held it in 7 quarters. The position peaked at $150K in Q4 2021. 7 funds tracked by Wall St. Rank hold AKTX as of Q3 2023.

  • Bryn Mawr Capital Management reported no remaining Akari Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bryn Mawr Capital Management sold 125 Akari Therapeutics shares in Q3 2023, an estimated $17K.
  • Bryn Mawr Capital Management first reported a position in Akari Therapeutics in Q4 2021 and held it in 7 quarters.
  • Bryn Mawr Capital Management's Akari Therapeutics position peaked at $150K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2023.

Based on Bryn Mawr Capital Management's 13F filing for Q3 2023, filed 8 Nov 2023.